Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast

Breast Cancer Research and Treatment

Volumn 126, Issue 1, 2011, Pages 241-245

  Lopez Bonet, Eugeni ^a,b,c   Pérez Martínez, Maria Carmen ^a,c   Martin Castillo, Begoña ^c,d   Alonso Ruano, Miguel ^a,c   Tuca, Francesc ^a,c   Oliveras Ferraros, Cristina ^c,d   Cufí, Sílvia ^c,d   Vazquez Martin, Alejandro ^c,d   Beltràn, Miquel ^c,d   Bernadó, Luis ^a,c   Menendez, Javier A ^c,d  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GROSS CYSTIC DISEASE FLUID PROTEIN 15; HORMONE RECEPTOR; MAMMAGLOBIN; PROGESTERONE RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; BREAST CARCINOMA; CANCER INCIDENCE; CYTOLOGY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; LETTER; NEUROENDOCRINE DISEASE; OCCULT CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; UPREGULATION;

EID: 79151485989     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1229-9     Document Type: Letter

References (17)

1. WHO (2003) World Health Organization classification of tumors. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyib, pp 9-112
2. I Günhan-Bilgen O Zekioglu EE Ustün A Memis Y Erhan 2003 Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings Eur Radiol 13 788 793 12664118 (Pubitemid 36790562)
3. Kawasaki T, Nakamura S, Sakamoto G et al (2010) Neuroendocrine ductal carcinoma in situ of the breast: cytological features in 32 cases. Cytopathology. (Epub ahead)
4. L Righi A Sapino C Marchiò M Papotti G Bussolati 2010 Neuroendocrine differentiation in breast cancer: established facts and unresolved problems Semin Diagn Pathol 27 69 76 10.1053/j.semdp.2009.12.003 20306832
5. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
6. B Weigelt FC Geyer HM Horlings, et al. 2009 Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type Mod Pathol 22 1401 1414 1:CAS:528:DC%2BD1MXhtlegsbzP 10.1038/modpathol.2009.112 19633645
7. C Richter-Ehrenstein J Arndt AC Buckendahl, et al. 2010 Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat 124 413 417 1:CAS:528:DC%2BC3cXht12qur3P 10.1007/s10549-010- 1178-3 20872069
8. E Lopez-Bonet M Alonso-Ruano G Barraza, et al. 2008 Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling Oncol Rep 20 1369 1374 19020716
9. R Bhargava S Beriwal DJ Dabbs 2007 Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity Am J Clin Pathol 27 103 113 10.1309/TDP92PQLDE2HLEET (Pubitemid 46797025)
10. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
11. E Caputo G Manco L Mandrich J Guardiola 2000 A novel aspartyl proteinase from apocrine epithelia and breast tumors J Biol Chem 275 7935 7941 1:CAS:528:DC%2BD3cXitVyltrc%3D 10.1074/jbc.275.11.7935 10713110 (Pubitemid 30159702)
12. A Sapino L Righi P Cassoni, et al. 2001 Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women Mod Pathol 14 768 776 1:STN:280:DC%2BD3MvlvFSkuw%3D%3D 10.1038/modpathol.3880387 11504836 (Pubitemid 33069835)
13. N Honma K Takubo F Akiyama, et al. 2005 Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast Histopathology 47 195 201 1:STN:280:DC%2BD2Mzoslyntw%3D%3D 10.1111/j.1365-2559. 2005.02181.x 16045781 (Pubitemid 41113123)
14. A Esparís-Ogando A Ocaña R Rodríguez-Barrueco, et al. 2008 Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells Ann Oncol 19 1860 1869 10.1093/annonc/mdn406 18641009
15. R Bhargava S Beriwal JM Striebel DJ Dabbs 2010 Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR Appl Immunohistochem Mol Morphol 18 113 118 1:CAS:528:DC%2BC3cXitlegtrs%3D 10.1097/PAI. 0b013e3181b94ff1 19801938
16. S Vranic O Tawfik J Palazzo, et al. 2010 EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast Mod Pathol 23 644 653 1:CAS:528:DC%2BC3cXlsFSjsbg%3D 10.1038/modpathol.2010.50 20208479
17. B Wei T Ding Y Xing, et al. 2010 Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma Cancer 116 4463 4473 10.1002/cncr.25352 20572042